Shots:

• The companies collaborated to evaluate the efficacy and safety of SOTIO’s SOT101 (IL-15 superagonist) + MSD’s Keytruda in the P-II (AURELIO-04) study in 300 patients with selected advanced/refractory solid tumors across the US & EU for six different indications. The study is expected to initiate in H1’22
• SOT101 + Keytruda showed promising clinical efficacy across multiple indications in the ongoing P-I/Ib (AURELIO-03) study
• SOT101 demonstrated a strong preclinical in vivo efficacy in multiple tumor models that showed increased long-term survival and tumor regression along with a favorable toxicology profile

 Ref: Globe Newswire | Image: MSD